Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy

This study has been completed.
Sponsor:
Collaborator:
Department of Health, United Kingdom
Information provided by:
Imperial College London
ClinicalTrials.gov Identifier:
NCT00159250
First received: September 8, 2005
Last updated: February 22, 2010
Last verified: February 2010